Education
About Us
Working with TipRanks
Follow Us
Iovance Biotherapeutics (IOVA)
:IOVA
IOVA Stock Chart & Stats
$2.30
-$0.33(-4.53%)
At close: 4:00 PM EST
$2.30
-$0.33(-4.53%)
Day’s Range― - ―
52-Week Range$1.64 - $9.70
Previous CloseN/A
Volume2.95M
Average Volume (3M)16.49M
Market Cap
$913.03M
Enterprise Value$541.65M
Total Cash (Recent Filing)$300.80M
Total Debt (Recent Filing)$52.49M
Price to Earnings (P/E)―
Beta1.98
Next Earnings
Mar 03, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding396,967,960
10 Day Avg. Volume26,544,982
30 Day Avg. Volume16,486,462
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)3.02
Price to Sales (P/S)13.07
P/FCF Ratio-5.89
Enterprise Value/Market Cap0.59
Enterprise Value/Revenue2.16
Enterprise Value/Gross Profit5.58
Enterprise Value/Ebitda-1.47
Forecast
1Y Price Target
$6.50Price Target Upside182.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentsThe company announced positive NSCLC data that represent key validation of the TIL strategy and road-map to drive future value.
Financial PerformanceShares are up ~28% on what is believed to be positive read through from improvements in gross margins and cost saving.
Regulatory ApprovalsHealth Canada recently approved AMTAGVI for metastatic melanoma, and potential approvals are anticipated in the United Kingdom and Australia in the first half of 2026 and Switzerland in 2027.
Bears Say
Financial EstimatesThe 2025 Amtagvi estimate was slightly decreased to $230MM.
Investor ConfidenceIovance is squarely in the investor's penalty box.
Share PerformanceAfter a pre-market spike, early share performance is essentially flat and still trades below its 20- and 50-day moving averages.
Iovance Biotherapeutics News
IOVA FAQ
What was Iovance Biotherapeutics’s price range in the past 12 months?
Iovance Biotherapeutics lowest stock price was $1.64 and its highest was $9.70 in the past 12 months.
What is Iovance Biotherapeutics’s market cap?
Iovance Biotherapeutics’s market cap is $913.03M.
When is Iovance Biotherapeutics’s upcoming earnings report date?
Iovance Biotherapeutics’s upcoming earnings report date is Mar 03, 2026 which is in 96 days.
How were Iovance Biotherapeutics’s earnings last quarter?
Iovance Biotherapeutics released its earnings results on Nov 06, 2025. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.258 by $0.008.
Is Iovance Biotherapeutics overvalued?
According to Wall Street analysts Iovance Biotherapeutics’s price is currently Undervalued.
Does Iovance Biotherapeutics pay dividends?
Iovance Biotherapeutics does not currently pay dividends.
What is Iovance Biotherapeutics’s EPS estimate?
Iovance Biotherapeutics’s EPS estimate is -0.16.
How many shares outstanding does Iovance Biotherapeutics have?
Iovance Biotherapeutics has 396,967,960 shares outstanding.
What happened to Iovance Biotherapeutics’s price movement after its last earnings report?
Iovance Biotherapeutics reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.258. Following the earnings report the stock price went up 27.624%.
Which hedge fund is a major shareholder of Iovance Biotherapeutics?
Currently, no hedge funds are holding shares in IOVA
Iovance Biotherapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.50 (182.61% Upside)
$6.50 (182.61% Upside)
Blogger Sentiment
Bullish
IOVA Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 12.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 5.2%
Last 30 Days ▲ 5.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.27%
12-Months-Change
Fundamentals
Return on Equity
-53.89%
Trailing 12-Months
Asset Growth
-8.69%
Trailing 12-Months
Company Description
Iovance Biotherapeutics
Iovance Biotherapeutics, Inc. is a biotechnology company focused on developing and commercializing cell therapy products for cancer treatment. The company's core technology centers on tumor-infiltrating lymphocyte (TIL) therapy, which harnesses the patient's own immune cells to target and destroy cancer cells. Iovance is primarily engaged in the research and development of innovative therapies for solid tumors, with its lead product candidate, lifileucel, aimed at treating metastatic melanoma and other cancers.
IOVA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was largely positive, highlighting significant revenue growth, successful strategic restructuring, and promising clinical data in lung cancer. However, challenges remain in expense management, global market expansion, and community ATC adoption.View all IOVA earnings summariesIOVA Stock 12 Month Forecast
Average Price Target
$6.50
▲(182.61% Upside)
Technical Analysis
KalVista Pharmaceuticals
―
Vir Biotechnology
―
Immatics
―
Nuvation Bio
―
Amylyx Pharmaceuticals Inc
―
Ownership Overview
0.29% Insiders
11.34% Mutual Funds
1.73% Other Institutional Investors
74.50% Public Companies and Individual Investors